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AMINOGLYCOSIDE RESISTANCE GENES IN Pseudomonas aeruginosa  
ISOLATES FROM CUMANA, VENEZUELA
Bertinellys TEIXEIRA(1), Hectorina RODULFO(1), Numirin CARREÑO(1), Militza GUZMÁN(2), Elsa SALAZAR(2) & Marcos DE DONATO(1)
SUMMARY
The enzymatic modification of aminoglycosides by aminoglycoside-acetyltransferases (AAC), aminoglycoside-adenyltransferases 
(AAD), and aminoglycoside-phosphotransferases (APH), is the most common resistance mechanism in P. aeruginosa and these 
enzymes can be coded on mobile genetic elements that contribute to their dispersion. One hundred and thirty seven P. aeruginosa 
isolates from the University Hospital, Cumana, Venezuela (HUAPA) were evaluated. Antimicrobial susceptibility was determined by 
the disk diffusion method and the aac, aadB and aph genes were detected by PCR. Most of the P. aeruginosa isolates (33/137) were 
identified from the Intensive Care Unit (ICU), mainly from discharges (96/137). The frequency of resistant P. aeruginosa isolates was 
found to be higher for the aminoglycosides tobramycin and amikacin (30.7 and 29.9%, respectively). Phenotype VI, resistant to these 
antibiotics, was the most frequent (14/49), followed by phenotype I, resistant to all the aminoglycosides tested (12/49). The aac(6´)-
Ib, aphA1 and aadB genes were the most frequently detected, and the simultaneous presence of several resistance genes in the same 
isolate was demonstrated. Aminoglycoside resistance in isolates of P. aeruginosa at the HUAPA is partly due to the presence of the 
aac(6´)-Ib, aphA1 and aadB genes, but the high rates of antimicrobial resistance suggest the existence of several mechanisms acting 
together. This is the first report of aminoglycoside resistance genes in Venezuela and one of the few in Latin America.
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INTRODUCTION
The aminoglycosides tobramycin, gentamicin, and amikacin 
are commonly used to treat hospital-acquired infections caused by 
Pseudomonas aeruginosa. These infections generally require treatment 
with a combination of antimicrobials in order to achieve a greater 
bactericidal effect and reduce the levels of resistance1. The use of a 
combination of antimicrobials, however, is associated with resistance 
mediated by aminoglycoside modifying enzymes (AME). Four of these 
enzymes, encoded by aac(6’)-I, aac(6’)-II, ant(2’’)-I, and aph(3’)-VI, 
are of particular significance because they are among the most common 
modifying enzymes present in P. aeruginosa, and their substrates are the 
most important antipseudomonal aminoglycosides2. The spread of these 
enzymes can occur through genetic elements exchanged between the 
same or different taxa, and is favored by the selective pressures present 
in a hospital environment where there is a constant use of antimicrobial 
compounds. This has led to bacterial resistance which is becoming an 
increasing threat to public health3.
In recent years, there has been an increased interest in studying the 
mechanisms of resistance associated with the different antimicrobial 
families used in clinical practice. According to epidemiological studies, 
Latin America is one of the regions with the highest incidence of 
hospital-associated outbreaks produced by bacteria resistant to several 
antibiotics4,5. Different patterns of resistance to betalactamics, quinolones 
and aminoglycosides have been reported in Mexico6, Peru7, Brazil8, and 
Venezuela9,10,11, and in Latin American surveys12, showing an increase 
in resistance in the P. aeruginosa strains. 
Genes resistant to aminoglycosides in this species have, however, 
only been reported in Europe, where aac(6´)-II and ant(2´´)-I are the 
most prevalent enzymes, and Korea where the most frequent enzymes 
are aph(3′)-VI, ant(2´´)-I, and aac(6´)-I, acting either on their own 
or in combination1. In Mexico and Brazil aac(6´)-31/aadA1, and 
aadA2 have also been reported in Hospital-acquired strains13,14. In 
Venezuela there have been no studies of genes that confer resistance 
to aminoglycosides in P. aeruginosa. However, these genes have been 
reported in Enterobacteria, with aadA, aadB, and aac(6)-Iq genes being 
the most frequently detected in a class I integron, in strains of Klebsiella 
pneumoniae from the University Hospital Antonio Patricio de Alcala 
(HUAPA), in Cumana, Venezuela15. Resistance in clinically important 
gram-negative bacteria is a growing concern which in recent years has 
broken the within-hospital barrier and is now also affecting outpatients. 
Bearing this information in mind, we evaluated the in vitro antimicrobial 
resistance of hospital-acquired strains of P. aeruginosa isolated from 
HUAPA and identified their resistant genes to aminoglycosides. We hope 
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that this will broaden our understanding of the different aminoglycoside 
resistance genes, and the mechanisms of resistance in the P. aeruginosa 
strains present in this hospital.
METHODS
We studied 137 different isolates of Pseudomonas aeruginosa, from 
patients with diagnosis of infection, attending different units within the 
HUAPA, from September 2010 to December 2011. For the identification 
of bacteria, the isolates were grown in Luria Bertani (LB) agar and 
taken to the Molecular Genetics Laboratory at the Research Institute 
of Biomedical and Applied Science “Dra. Susan Tai”, Universidad de 
Oriente (IIBCAUDO), where they were kept until their analysis. Isolates 
were taken only from those patients who had signed a written consent 
form, after complete disclosure of the aims, risks, and scope of the 
research project was given. Treatment of patients, analysis of isolates, 
and information generated was conducted according to the bioethical and 
biosafety guidelines as stated by the Bioethics and Biosafety Commission 
of the IIBCAUDO (CoBioBios).
To define the presence of infection, we used the criteria established 
by the Spanish Society of Infectious Diseases and Clinical Microbiology 
(http://www.seimc.org/documentoscientificos.php?mn_MP=3&mn_
MS=358). In addition, an infection was considered a Healthcare-
associated Infection (HAI) if the date of detection of the site-specific 
infection, as defined by the US National Healthcare Safety Network 
(NHSN), had taken place after the 3rd day of admission to an inpatient. 
Otherwise, they were regarded as a community-acquired infection (the 
infection was already present on the day of admission). 
Bacteriological Diagnosis 
The viability and purity of the isolates was confirmed using standard 
culture and biochemical tests, according to the procedures and protocols 
for the identification of non-fermenting gram-negative bacilli17. Microbial 
susceptibility was determined by the disc diffusion method18 using the 
following antimicrobials (BD): amikacin (30 μg), gentamicin (10 μg), 
netilmicin (30 μg), tobramycin (30 μg), ciprofloxacin (5 μg), cefepime 
(30 μg), ceftazidime (30 μg), piperacillin (30 μg), piperacillin/tazobactam 
(100/10 μg), meropenem (10 μg), imipenem (10 μg), and aztreonam (30 
μg), according to the guidelines proposed by the Clinical Laboratory 
Standard Institute for P. aeruginosa19. 
Molecular identification of aminoglycoside resistance genes 
Bacterial genomic DNA was extracted using the Kit Wizard® 
Genomic (Promega) according to the manufacturer instructions 
for gram-negative bacteria. The genes coding for aminoglycoside 
resistance: aac(3)-IIa (aacC2-F/R 5´-actgtgatgggatacgcgtc-3´/5´-
ctccgtcagcgtttcagcta-3´)20, aphA1 (aphA1-F/R 5´-atgggctcgcgataatgtc-
3 ´ / 5 ´ - c t c a c c ga g g c a g t t c c a t - 3 ´ )  a n d  a p h A 2  ( a p h A 2 - F / R 
5´-gaacaagatggattgcacgc-3´/5´-gctcttcagcaatatcacgg-3´)21, aac(6´)-Ib 
(aac(6´)-IbF/R 5´-taggagtggctaaatcgat-3´/5´-cccgctttctcgtagca-3´)22 and 
aadB (aadB-F/R 5´-cgtcatggaggagttggact-3´/5´-cgcaagacctcaaccttttc-3´)23 
were detected using PCR. Klebsiella pneumoniae strains Kp01, which 
contains the aac(3´)-IIa gene; Kp28, which contains the aac(6´)-Ib and 
aph genes; and KpM7, which contains the aadB gene, were used as 
positive controls15. The amplification products were run on a 2% agarose 
gel, stained with ethidium bromide (0.5 μg/ml) and buffered in TBE 1X, 
for 30 minutes at 100 V. 
RESULTS
From the total number of P. aeruginosa isolates obtained from 
different patients who were admitted to the HUAPA for various 
treatments, 83.2% (114/137) were identified from patients with hospital-
acquired infections. These infections were defined when the clinical and 
epidemiological information of each individual showed that the patients 
stayed at least 72 hours after they were admitted. Most isolates were 
from patients treated in the Medicine A-B unit (n = 46), in the intensive 
care unit (ICU) (n = 33), and in the nursery (n = 10). The patients treated 
were hospitalized over a long period (between 55 and 250 days, mean 
109 days) and were either immunosuppressed or in a critical condition.
The isolates were mainly from discharges, and were obtained from 
different parts of the body (96 isolates, 70.0%), followed by catheter 
tips (15 isolates), sputum (13 isolates), urine (7 isolates), blood (4 
isolates), and peritoneal liquid (2 isolates). It should be mentioned that 
the identification of P. aeruginosa from catheter tips was only undertaken 
when the bacterium was also isolated from a blood sample of the same 
patient.
The resistance profiles of the P. aeruginosa isolates showed that 
65.0% (89/137) were resistant to one or more antibiotics: 51.1% 
(70/137) were resistant to ciprofloxacin, 36.5% (50/137) to meropenem, 
35.0% (48/137) to imipenem, 32.8% (45/137) to piperacillin, and 
32.1% (44/137) to piperacillin-tazobactam (Fig. 1). In addition, 30.7% 
(42/137) and 29.9% (41/137) of the isolates showed resistance to the 
aminoglycosides tobramycin and amikacin, respectively. A total of 
9 aminoglycoside resistance profiles (phenotypes) were identified in 
the isolates (Table 1), of which, the most frequent was the phenotype 
VI, which showed resistance to tobramycin and amikacin, and type I, 
which was resistant to all of the aminoglycosides assayed. Furthermore, 
95.9% of the isolates with phenotype I also showed multidrug-resistant 
phenotypes.
The most frequent aminoglycoside resistance gene was aac(6´)-Ib, 
detected in phenotypes I, II, III, IV, VI, and VII (Table 2), followed by 
aphA1 (phenotypes I, IX, and VIII) and aadB (phenotypes I and V). 
These genes were also shown to be simultaneously present in all of the 
phenotype I strains, and in three of the phenotype VI strains.
Nevertheless, the results of the aminoglycoside resistant phenotypes 
did not always coincide with those of the resistance genes detected. Thus, 
10 of the isolates with phenotypic resistance to the aminoglycosides 
did not yield PCR amplification products for any of the genes evaluated 
in this study. Six isolates showed the presence of multidrug-resistant 
phenotypes (Table 3). Only two samples (phenotypes III and VII) came 
from outpatients (adult observation area). Isolates with phenotypes III 
and IV and 2 with phenotype VI showed a phenotype that suggests the 
presence of metallobetalactamases. 
DISCUSSION
Pseudomonas aeruginosa has become an important pathogen, 
constituting 10 to 15% of hospital-acquired infections worldwide, 
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especially in immunocompromised patients in ICUs24. These data agree 
with the findings of our study. Similar results have been reported in 
Mexico6 and in Caracas, Venezuela9. In addition, we found that 16.8% 
of community-associated infections were caused by P. aeruginosa. This 
is comparable to a study of patients from India suffering from acquired 
pneumonia in the community25, where P. aeruginosa was the second 
most frequent bacteria.
The high frequencies of P. aeruginosa isolates resistant to tobramycin 
and amikacin have also been reported in other health institutions. In 
Venezuela, in a study of Pseudomonas isolates collected in 30 different 
health institutions throughout the country during the years 1988-199826, 
the resistance shown to gentamicin was 27%, 19% to amikacin and 23% 
to tobramycin. In a collaborative study, where the resistance pattern of 586 
isolates from Argentina, Brazil, Chile, Colombia, Costa Rica, Ecuador, 
Guatemala, Mexico, Panama, Peru, and Venezuela12 were analyzed, the 
average resistance found for gentamicin was 32.6%, 24.6% for amikacin 
and 29.9% for tobramycin. Others studies in Latin American countries 
have shown a frequency of resistant isolates between 27.8- 42.0% for 
gentamicin and 16.3- 28.9% to amikacin27,28,29. In Spain, resistance 
frequencies of 24.2% to gentamicin and 16.7% to amikacin have been 
reported30.
The inactivation of aminoglycosides by modifying enzymes is the 
most common resistance mechanism in gram-negative bacilli. This was 
corroborated in this study performed at HUAPA, where the most frequent 
genes detected were aphA1, aadB and aac(6´)-Ib, with N-acetylation at 
the 6’ position catalyzed by the last enzyme, being the most usual ways 
in which aminoglycosides are modified by P. aeruginosa1,31.
Table 1
Resistance phenotypes, number of strains (N) and resistance to 
aminoglycosides in P. aeruginosa strains isolated from patients at the 
University Hospital in Cumana, Venezuela
Phenotype N Resistance to Amino-glycosides
I 12 GM NN NET AK
II 4 GM NN NET
III 7 GM NN AK
IV 4 NN NET AK
V 1 GM NN





GM: gentamicin; NN: tobramicin; NET: netilmicin; AK: amikacin.
Table 2
Resistance phenotypes and amplified genes in Pseudomonas aeruginosa strains 




aac(3´)-IIa aac(6´)-Ib aphA1 aphA2 aadB
I 3 - X X - X
I 1 - - X X X
I 5 - - X - X
I 2 - X - - X
I 1 - X - X X
II 4 - X - - -
III 5 - X - - -
IV 3 - X - - -
V 1 - - - - X
VI 1 X - - - -
VI 3 - X - - -
VI 3 - X - X -
VI 2 - - - X -
VII 1 - X - - -
VIII 1 - - X - -
IX 3 - - X - -
Total 39 1 25 13 7 13
Fig. 1 - Antimicrobial resistance in strains of P. aeruginosa isolated from patients at the University Hospital in Cumana, Venezuela. PIP: piperacillin, TZP: piperacillin/tazobactam, CAZ: 
ceftazidime, FEP: cefepime, ATM: aztreonam, IPM: imipenem, MEM: meropenem, GM: gentamicin, NN: tobramycin, NET: netilmicin, AK: amikacin, CIP: ciprofloxacin.
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This study has also demonstrated the simultaneous presence of 
several aminoglycoside resistance genes in all the phenotype I isolates, 
and in three of the phenotype VI strains evaluated. In Korea, the presence 
of aph(3’)-VI, aad(2’’)-I, and aac(6’)-I genes has been reported in 250 
isolates of P. aeruginosa32, where the genes were found either alone 
or combined, with aac(6’)-I + aad(2’’)-I being the most frequent 
combination (24/36 isolates). In Iran, aac(6´)-II (36%); aad(2´´)-I 
(28%), aph(3´)-VI (11%), and aac(6´) (7%) genes have been reported 
in P. aeruginosa strains, highlighting the fact that up to four different 
genes have been found simultaneously in the same isolate2. In this sense, 
integrons have been reported in Brazil13,33 and Mexico14, carrying multiple 
copies of aminoglycoside resistance genes. 
Several of the P. aeruginosa isolates showing phenotypic resistance 
to aminoglycosides evaluated in this study did not test positive for the 
resistance genes evaluated, this suggests that other genes, not tested here, 
which confer resistance to aminoglycosides, may be present in these 
isolates, as reported elsewhere2. Differences in the distribution of these 
enzymes could be derived from differences in the selective pressures on 
the bacterial population with respect to aminoglycoside utilization34. There 
are also other mechanisms that could lead to aminoglycoside resistance, 
that were not evaluated here, such as: changes in the permeability of the 
external membrane, active efflux systems, and alterations of the 30S 
ribosomal subunit conferred by mutations2,34,35. Active efflux systems 
have been demonstrated to be involved in the resistance of P. aeruginosa 
to aminoglycosides in several countries35,36. An explanation regarding 
the presence of resistance genes but not of phenotypic resistance, is the 
presence of mutations producing non-functional proteins and the lack of 
promoters in the upstream region where the genes are inserted37.
The multi-resistance observed in isolates that did not amplify the 
AME genes evaluated, were mainly obtained from inpatients undergoing 
long term treatments, and the individuals had received a combination of 
antimicrobials that could also be partly associated with the indiscriminate 
use of multiple treatment schemes with broad spectrum antimicrobials, 
favoring the increase of bacterial resistance caused by multiple 
mechanisms. However, the high frequency of resistance to different 
antimicrobials shown by the P. aeruginosa isolates from HUAPA suggests 
the existence of multiple resistance mechanisms acting together.
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